Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

Summary by ADKhabar
July 18, 2026 15:15 ET  | Source: 4D Molecular Therapeutics, Inc. After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE […] The post 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Tria…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

stocktitan.netstocktitan.net
Reposted by
ADKhabarADKhabar

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Saturday, July 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Emeryville icon

Emeryville

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal